For instance, the identification of reduced FGF-19 or FGF-22 levels in overweight individuals or those with type 2 diabetes could indicate a higher risk of metabolic decompensation and musculoskeletal deterioration [58,59]. This evidence concerns the gene FGF19 and type 2 diabetes mellitus.